Endocrine Abstracts

Introduction: The use of immunotherapy in oncology patients is increasing and is likely to continue to increase in the future. It is widely known that therapies have endocrinological side effects which can be serious, but maybe are also useful indicators to judge a response to the treatment. Presently, we do have not enough information regarding these side effects and their evolution.Materials and methods: Observational and retrospective study of 162 onc...

Introduction: Several clinical and molecular markers can be used to establish risk at the time of diagnosis in DTC. Thyroglobulin (Tg), which is essential in follow up, could be an early marker to identify risk patients. Around 25% of patients require 18 months or longer to have indetectable Tg. The presence of Tg antibodies (TgAb) invalidate the follow up of DTC via Tg and this is usually associated with a poor prognosis.Aim: To evaluate the role of Tg ...

Background and Objective: Semaglutide, a glucagon-like peptide 1 (GLP1a) receptor agonist, reduces the risk of major adverse cardiovascular events in patients with type 2 diabetes mellitus (DM2). An oral version of semaglutide is now available, and patients may prefer it to the subcutaneous form. Our objective was to compare the effectiveness and safety of both formulations in real life.Methods: Retrospective real-world efficacy analysis including aGLP1-...

Background: PREDIRCAM2 is a web platform for obesity treatment and follow-up. It contains modules for: dietary prescription and registry with nutritional analysis based on individualized and mediterranean dietary goals, physical activity prescription and tracking with individualized targets, and anthropometric tracking. An ongoing multicenter randomized clinical trial evaluates the intervention’s effectiveness in obesity treatment and cardio-metabolic-risk prevention....